Showing 181-190 of 220 results for "".
- Agents for Advanced Melanoma Among Prix Galien USA 2015 Award Recipientshttps://practicaldermatology.com/news/agents-for-melanoma-among-prix-galien-usa-2015-award-recipients/2458832/The Prix Galien USA 2015 Awards have been bestowed on Imbruvica® (ibrutinib) for best pharmaceutical agent, Opdivo® (nivolumab) and Keytruda® (pembrolizumab) for best biotechnology product, and the T2Candida Panel for best medical technology. 
- Phase 2 Psoriasis Study Shows Positive Results for Boehringer Ingelheim's Investigational Biologichttps://practicaldermatology.com/news/phase-2-psoriasis-study-shows-positive-results-for-boehringer-ingelheims-investigational-biologic/2458837/Results from a Phase II head-to-head psoriasis study show superior efficacy of Boehringer Ingelheim’s investigational biologic compound BI 655066 over ustekinumab. After nine months, 69 percent of patients with moderate-to-severe plaque psoriasis maintained PASI 90 with BI 655066, compared
- Novan's SB204 Demonstrates Positive Phase 2b Clinical Trial Results for the Treatment of Acne Vulgarishttps://practicaldermatology.com/news/novans-sb204-demonstrates-positive-phase-2b-clinical-trial-results-for-the-treatment-of-acne-vulgaris/2458863/Novan Therapeutics topical nitric oxide drug candidate SB204 for the treatment of acne vulgaris, demonstrated statistically significant reductions in the percent change of non-inflammatory (white heads and black heads) and
- Nerium International Announces Exclusive Usage of Anti-Aging Ingredient SIG-1273https://practicaldermatology.com/news/nerium-international-announces-exclusive-usage-of-anti-aging-ingredient-sig-1273/2458970/Nerium International added new ingredient, SIG-1273®, to the Optimera Formula of its Age-Defying Night and Day Creams. Engineered by Princeton University biochemist, Jeffry Stock, SIG-1273 is the result of 20 years of intensive biomedical skincare research, accordi
- Novan Secures $50 Million Private Financinghttps://practicaldermatology.com/news/novan-secures-50-million-private-financing/2458973/Novan Therapeutics, a clinical-stage biotechnology company focused on advancing innovation in dermatology via nitric oxide therapies, today announced that it has secured $50 million in an oversubscribed private financing. New investor Malin Corporation Plc. (MLC: ISE) functioned as the cornerston
- FDA Grants Bristol-Myers Squibb's Opdivo Accelerated Approval for Melanomahttps://practicaldermatology.com/news/fda-grants-bristol-myers-squibbs-opdivo-accelerated-approval-for-melanoma/2459039/The FDA approved Bristol-Myers Squibb’s Opdivo (nivolumab) injection, for intravenous use. Opdivo is a human programmed death receptor-1 (PD-1) blocking antibody indicated for the treatment of patients with unresectable or metastatic melanoma and disease progression following Yervoy (ipilim
- AMBI® Skincare Names Model Search Winnerhttps://practicaldermatology.com/news/20140623-ambi_skincare_names_model_search_winner/2459194/Charnee Long, 21, is the Grand Prize Winner of the first-ever nationwide AMBI® Model Search. Charnee was one of 10 finalists selected from a pool of more than 6,099 entrants. She will be featured in a national print campaign, receiving a three day/two night trip to New York City for a pro
- Two States Pass Laws Banning Indoor Tanning for Minorshttps://practicaldermatology.com/news/20140527-two_states_pass_laws_banning_indoor_tanning_for_minors/2459230/Minnesota and Louisiana have both recently passed legislation banning the use of indoor tanning facilities for those under 18 years of age. Both laws go into effect on August 1, 2014. Nine states in total have instituted bans on indoor tanning for minors, including Vermont, California, Illinois, Ore
- Novan Therapeutics to Present Data at 2014 Society for Investigative Dermatology Annual Meetinghttps://practicaldermatology.com/news/20140425-novan_therapeutics_to_present_data_at_2014_society_for_investigative_dermatology_annual_meeting/2459255/Novan Therapeutics, a specialty pharmaceutical company focused on advancing nitric oxide therapies for a number of diseases, will present data from the Phase 2 clinical trial in acne vulgaris with its lead product candidate, SB204, at the 2014 Annual Meeting of the Society for Investigative Dermatol
- Alma Lasers Hosts Special Programs at the 34th ASLMS Conference in Phoenixhttps://practicaldermatology.com/news/20140403-alma_lasers_hosts_special_programs_at_the_34th_aslms_conference_in_phoenix/2459279/The ASLMS, provider of laser, light-based, radio frequency and ultrasound technologies, invites guests to hear from leading experts. Michael Gold, of Gold Skin Care in Nashville, Tennessee, will moderate the night's discussion. Others include: Macrene Alexiades-Armenakas, MD, director a